Across TCGA pan-cancer cohorts, ILRUN mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ILRUN data layer compared with 18 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ILRUN mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ILRUN expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ILRUN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.364	0.977	.002	38	view →
LUAD	DFS	Tertile	All	0.436	0.715	.022	6	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.355	.012	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ILRUN tumor-vs-normal RNA expression · all ILRUN data types